COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH INC.Security Agreement • July 31st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ____, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASPIRA WOMEN’S HEALTH INC., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CONFIDENTIAL Aspira Women’s Health Inc. Attention: Nicole Sandford 12117 Bee Caves Road, Building III Suite 100 Austin, TX 78738Financial Advisory Agreement • July 31st, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Aspira Women’s Health Inc. (the “Company”) to render Financial Services (as defined below) to the Company.
